Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 327  

 
   Table of Contents      
BOOK REVIEW
Year : 2013  |  Volume : 12  |  Issue : 3  |  Page : 5-6

Theranostics, Gallium‑68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment: Proceedings of the 1st World Congress on Gallium-68 and Peptide Receptor Targeted Radiation Therapy, Bad Berka, Germany, June 2010


Department of Radiology, The University of Iowa, Iowa City, IA 52246, USA

Date of Web Publication23-May-2013

Correspondence Address:
Michael K Schultz
Department of Radiology, The University of Iowa, Iowa City, IA 52246
USA
Login to access the Email id


Rights and Permissions

How to cite this article:
Schultz MK. Theranostics, Gallium‑68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment: Proceedings of the 1st World Congress on Gallium-68 and Peptide Receptor Targeted Radiation Therapy, Bad Berka, Germany, June 2010. World J Nucl Med 2013;12, Suppl S1:5-6

How to cite this URL:
Schultz MK. Theranostics, Gallium‑68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment: Proceedings of the 1st World Congress on Gallium-68 and Peptide Receptor Targeted Radiation Therapy, Bad Berka, Germany, June 2010. World J Nucl Med [serial online] 2013 [cited 2020 May 27];12, Suppl S1:5-6. Available from: http://www.wjnm.org/text.asp?2013/12/3/5/107274




Editors: R.P. Baum, F. Rosch

Publisher: Springer, Heidelberg

Recent Results in Cancer Research Vol. 194,

Year 2012

ISBN: 978-3-642-27993-5

The general themes of this book (Theranostics and peptide receptor targeted radiotherapy) derive from evolving successes in the use of generator-produced gallium-68 ( 68 Ga) for molecular imaging of disease. The chapters contributed represent an excellent synopsis of the scientific developments presented at the 1 st World Congress on Gallium-68 and Peptide Receptor Targeted Radiation Therapy (June, 2010), which attracted over 300 investigators (from over 50 countries) to Bad Berka, Germany for the scientific event.

The use of 68 Ga for molecular imaging of disease has seen a remarkable increase over the last several years. Applications for 68 Ga positron emission tomography (PET) are emerging across a broad spectrum of diagnostic imaging challenges, including cancer, cardiovascular disease, infection, and inflammation. The increase in enthusiasm for 68 Ga use can be ascribed to several factors, including: Superiority in achievable image quality compared to other gamma-emitting radionuclides (e.g., indium-111), nuclear decay characteristics (i.e., half-life and positron emission branching ratio) that are considered favorable for clinical molecular imaging, and the potential for on-demand production via the introduction of maturing-competitive generator and fluid handling technologies that are now capable of providing reliable, high-purity, on-demand 68 Ga precursor in sufficient quantities for routine radiopharmaceutical production in the absence of cyclotron operations. These characteristics promise an increasing role for 68 Ga as a tool for the design of compounds that have both diagnostic and therapeutic attributes (i.e., Theranostics).

The book is organized into four sections: Part I details the history of 68 Ga generators and highlights recent advances in radiochemistry, generator technology, and fluid handling systems that provide the basis to advance new 68 Ga (and compounds labeled with therapeutic radionuclides, such as lutetium-177, 177 Lu) to clinical application for patient care; Part II provides a broad review of the potential for 68 Ga and peptide receptor targeted molecular imaging and radiotherapy through contributions, highlighting the potential of 68 Ga for labeling of peptides, small molecules, nanoparticles, antibodies, and affibodies; Part III focuses on clinical molecular imaging applications for 68 Ga, with a heavy focus on the success of radiolabeled peptides targeted to the somatostatin subtype II receptor for imaging of neuroendocrine tumors, but also includes an interesting application for 68 Ga for lung perfusion imaging; Part IV provides excellent contributions highlighting recent success in Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) using 177 Lu and includes Dosimetry contributions that can provide researchers with excellent background materials needed to consider the introduction of new radiolabeled peptides for PRRT and diagnostic imaging.

This book is an excellent resource for investigators interested in gaining a detailed understanding of the state-of-the-art 68 Ga and PRRT-based Theranostics for preclinical and emerging clinical applications.




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article

 Article Access Statistics
    Viewed1327    
    Printed51    
    Emailed0    
    PDF Downloaded254    
    Comments [Add]    

Recommend this journal